Anticorps Anti - TNNI3K produit en lapin, environ 1 mg / mL, anticorps isolé affinité, solution aqueuse tamponnée

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Overexpression of TNNI3K (TNNI3 interacting kinase) may induce and increase cardiac myogenesis and performance respectively. It also might inhibit ventricular remodeling, caused by ischemia. TNNI3K might be associated with the development of cardiac hypertrophy. TNNI3K is known to be associated with atrioventricular conduction disease, acute coronary syndrome and obesity.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

General description

Anti-TNNI3K antibody detects endogenous levels of total TNNI3K protein.

The TNNI3K (TNNI3 interacting kinase) gene is a novel cardiac troponin I-interacting kinase gene and is mapped to human chromosome 1p31.1. The gene is expressed in cardiomyocytes. The encoded protein belongs to mitogen-activated protein kinase kinase kinase (MAPKKK) family. Tnni3k consists of seven to ten ankyrin repeats at the N terminal, a Ser/Thr and Tyr kinase domain, and a Ser-rich domain at the C-terminal.

Immunogen

The antiserum was produced against synthesized peptide derived from human TNNI3K.Immunogen Range: 301-350

Physical form

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.